The OpenCRISPR initiative aims to democratize gene technology and accelerate the development of customized genetic treatments. By making this technology available, Profluent hopes to increase access and reduce the costs of gene editing treatments.
Scientists have used CRISPR technology to create tomatoes that use water more efficiently. These tomatoes require less water to grow but still produce the same amount of tomatoes, with the same taste and quality.
For the first time, surgeons have transplanted a kidney from a genetically modified pig into a living person. This type of kidney could help reduce the shortage of organs.
The FDA recently approved a pioneering CRISPRβCas9 therapy for sickle cell disease, marking a historic moment in genetic treatment. But that it is just the tip of the iceberg.
The approvals include the first-ever CRISPR-Cas9 based drug, Casgevy, and a gene therapy drug, Lyfgenia, marking a milestone in medical biotechnology.
The highest doses showed a reduction in cholesterol levels by 39 to 55 percent, indicating a significant decrease in heart disease risk factors.
In groundbreaking use of CRISPR gene-editing technology, scientists have engineered flu-resistant chickens. This is a first step towards reducing avian flu outbreaks.
Bacteria use a "scissors" system called CRISPR-Cas against viruses, and scientists have now discovered that complex cells, like ours, have a similar tool too.